Impact and evolution of minimal invasive surgery in a centralized colorectal service: trends, safety and oncological outcomes across 15 years Authors: Ali Toffaha, Mahmood Al-Dhaheri, Sherif Ahmed, Ayman Ahmed, Ibrahim Amer, Mahwish khawar, Ammar Aleter, Ejaz Latif, Hamza A Abdul-Hafez, Salwa Ahmed, Mohammed Yousif, Noof Al Naimi, Mohamed A Kurer, Amjad Parvaiz, Mohamed Abunada Published: 2025 ABSTRACT AbstractAimSpecialization with subsequent evolving minimally invasive surgery (MIS) has been increasingly adopted in colorectal cancer care. This study aims to evaluate the impact of centralization and team specialization on oncologic quality and patient safety in colorectal cancer over 15 years by comparing an early phase with a later (post-specialization) phases; and to describe trends in MIS adoption over unit’s progression period with the framework of MIS adoption.MethodsA retrospective cohort study that included all elective oncologic colorectal resections at a tertiary referral center for the past 15 years. Data was analyzed in five cohorts with timeline intervals consisting of three years duration from 2010 to 2024. Outcomes included MIS utilization, conversions, R0 resection, lymph node adequacy (≥ 12), major complications (Clavien–Dindo ≥ III), reoperation for leak, and length of stay (LOS).ResultsAmong 1,142 colorectal cancer resections, MIS adoption rose from 51.2% in 2012 to 93.6% in 2024. Robotic surgery, introduced in 2017, accounted for 31% of cases by 2022–2024. Oncologic quality improved significantly (R0 resection 87.6% to 96.0%, ≥ 12 nodes 88.8% to 96.9%; both p < 0.001). Major complications decreased from 12.3% to 8.8% and reoperation for leak from 4.3% to 2.1%. Mean LOS was 6.4 days for MIS vs. 8.4 days for open (p < 0.001), reducing to 5.5 days for MIS in 2024.ConclusionA phased centralization and specialization in colorectal unit enabled safe and effective adoption of laparoscopic and robotic surgery. In addition to increased proportion of colorectal resection being done using MIS technique, improved clinical and oncological outcomes were seen during the study period and unite development. MIS consistently shortened hospital stay without compromising safety, affirming its role as the standard in specialized care.Keywords: Minimal invasive surgery, Colorectal cancer, Colorectal surgery, Robotic surgery, Gastrointestinal malignancy Introduction Colorectal cancer is the third most commonly diagnosed malignancy worldwide, contributing significantly to cancer-related mortality and morbidity [1, 2]. Advances in surgical techniques over the past three decades have transformed the therapeutic landscape, particularly with the rise of minimally invasive surgery (MIS), including laparoscopic, robotic, and endoscopic approaches. MIS has become the standard of care in colorectal cancer management [3–5]. However, adoption of MIS for rectal cancer has been more gradual, due to anatomical complexity and functional concerns [5]. To overcome these challenges, the robotic surgical platform has been increasingly utilized, offering three-dimensional visualization, enhanced instrument dexterity, stable camera control, and elimination of tremors, particularly in the narrow pelvic cavity [5]. Beyond surgical approach, patient outcomes are strongly influenced by surgeon subspecialization and institutional volume. Multiple population-based studies and meta-analyses demonstrate that colorectal cancer patients treated by colorectal specialists and in high-volume centers experience improved short and long-term outcomes, including higher rates of optimal resection, lower perioperative mortality, fewer complications/reoperations, greater use of MIS, and better survival- when compared with care delivered by general surgeons or low-volume providers [6]. Contemporary commentaries and national data further argue for service centralization and specialist-led rectal cancer programs, given the technical demands of high-quality TME and pelvic nerve preservation [7]. This context supports our institution’s structured subspecialty pathway for colorectal surgery unit, MIS adoption and quality assurance. We conducted a retrospective cohort study to evaluate the impact of centralization and team specialization on oncologic quality and patient safety in colorectal cancer over 15 years by comparing an early phase with a later (post-specialization) phases; and to describe trends in MIS adoption over unit progression period with the framework of specialization and MIS adoption. Methodology Study design and setting We performed a retrospective observational cohort study of adult patients (≥ 18 years) who underwent elective oncologic colorectal resections for primary colorectal malignancy at tertiary center between January 2010 and December 2024. The study took place at Hamad medical corporation (HMC), Qatar. Key service milestones included the establishment of a centralized specialist colorectal surgery unit in 2010, to which all colorectal cancer cases over the country were referred; the introduction of a multidisciplinary tumor board in 2011; and the introduction of robotic colorectal resection in 2017 whist the structured robotic colorectal program got established in 2020. Data collection and patient selection Using electronic medical record, operative notes, histopathology reports, and multidisciplinary team records, we include consecutive adults (≥ 18 years) who underwent elective oncologic colorectal resections with curative intent for primary colorectal cancer between 1 January 2010 and 31 December 2024. Patients who have non-primary colorectal neoplasms, underwent emergency or palliative resections, or underwent local excisions without formal oncologic resection (endoscopic or transanal local excision) were excluded from the study. Also, we exclude any records lacking essential data for the study. Surgical procedures Operations adhered to oncologic principles with standardized mesocolic/mesorectal dissection, multivisceral or enblock resection of any involved nearby structure was undertaken when needed with the aim to achieve R0 resection. Surgical approaches included open, laparoscopic, and robotic platforms; conversions is defined by any open incision to facilitate tumor mobilization or achieving vascular control during the MIS procedure. Extraction site incision was only utilized for extraction of specimens. Variables and outcomes Baseline variables included patient demographics (age, sex, body mass index [BMI]) and physiological status (American Society of Anesthesiologists [ASA] classification). Tumor-related variables comprised the primary tumor site and distance from the anal verge as documented in preoperative assessment and operative notes. Operative variables intended surgical approach (open, laparoscopic, robotic) and conversion status (defined as an intended minimally invasive procedure completed via laparotomy). Primary oncologic outcomes were R0 resection (negative longitudinal and radial margins on final pathology) and lymph node adequacy (≥ 12 nodes retrieved). Safety outcomes were major postoperative complications defined as Clavien–Dindo grade ≥ III and reoperation for anastomotic leak. We also reported the postoperative length of stay (LOS), calculated in days from day of surgery to hospital discharge for the index admission. Implementation framework We implemented a four-phase framework aligned with the launch of a specialized colorectal pathway. Each phase included predefined training, supervision, credentialing checkpoints, governance, and audit/feedback (Table 1). Table 1Phased implementation timeline and key activitiesPhase & TimingScope & IndicationsTraining & SupervisionCredentialing & ThresholdsPhase 0 (− 6–0 mo)Pathway setup, registry, ERAS, MDT weeklySimulation basics; OR brief–debrief; checklistsN/A (pre-implementation)Phase 1 (0–18 mo)Low-complexity colectomyProctored cases; daily huddles≥ 10 supervised cases; conversion < 20%; checklist ≥ 80%Phase 2 (18–36 mo)Intermediate incl. select rectalcadaveric/animal lab; monthly video M&MAdditional ≥ 20 cases; conversion ≤ 15%; leak ≤ benchmarksPhase 3 (≥ 36 mo)Full spectrum (credentialed)Targeted sim; quarterly dashboardAnnual ≥ 25 MIS colorectal cases/surgeon; re-credential if below Phased implementation timeline and key activities Phase 0 Foundation (At the beginning): Established a pathway governance (lead surgeon, nurse coordinator, anesthesiology lead), limited all oncologic colorectal operations to the specializing unit, defined colorectal MDT (weekly) with MDT coordinator and cancer pathway coordinator who streamline the red flagged referrals to be seen by surgeons within 48 h, have finalized their investigations and started management within 4 weeks of first referral. Established a data registry with core KPIs (R0 rate, lymph-node yield, conversion, leak, LOS, readmission, 30-day mortality). Training: laparoscopy simulation curriculum, program of visiting experienced laparoscopic colorectal surgeons; standardized intraoperative checklists and anastomosis bundles, surgical site infection bundles (SSI). Phase 1 Supervised Introduction (0–18 months): Introduced MIS for low-complexity right/left colectomy under proctoring by an experienced colorectal MIS surgeon. Surgeons of the unit were also sent on training courses in MIS specialized centers. Credentialing phase1: minimum 10 supervised MIS colectomies (≥ 80% checklist adherence; conversion < 20% without safety compromise; no unaddressed critical incidents). Escalation policy: explicit criteria for early conversion; mandatory intraoperative consult triggers (e.g., bleeding > 500 mL, unclear planes, unplanned organ injury), with these triggers the lead surgeon was always notified. Phase 2 Consolidation (18–36 months): Expanded indications (including select rectal resections with TME in carefully staged cases). Training: Animal and cadaveric lab for pelvic dissection; video-based peer review at monthly M&M. Credentialing phase 2: additional 20 MIS cases with complexity ladder (simple → intermediate), leak ≤ published benchmarks for case-mix; maintain conversion ≤ 15% for intermediate cases. Introduced standardized ICG perfusion assessment and anastomosis bundles where available. Phase 3 Optimization (≥ 36 months): full indication spectrum by credentialed surgeons and introduction of MIS for multivisceral resection and locally advanced tumors; cross-coverage within the specialized team to maintain volume thresholds. Annual maintenance: ≥25 MIS colorectal resections/surgeon; targeted simulation for rare complications; quarterly KPI dashboard review with corrective action plans when any metric drifts beyond control limits. Establishment of colorectal surgery fellowship which was 4 years, fellows were able by the end of their training to do complex colorectal MIS independently. And they shall pass the European board of coloproctology as an exit exam. For Robotic adoption which started from 2017, the surgeons of the unit with prior laparoscopic colorectal experience were enrolled in the training program. The training program adopted the European Academy for Robotic Colorectal Surgery (EARCS) model [8] and led by expert robotic and laparoscopic surgeon. Each trainee went through a series of assessment-based modules. This was subsequently augmented with a practical hands-on clinical component. The curriculum included the following modules: Theoretical knowledge development using lectures and cadaveric videos covering the pelvic anatomy and anatomy related to Total Mesorectal Excision (TME) [9]. Theoretical knowledge development using lectures and cadaveric videos covering the pelvic anatomy and anatomy related to Total Mesorectal Excision (TME) [9]. Online Training on the robotic system as per Intuitive curriculum [10]. Online Training on the robotic system as per Intuitive curriculum [10]. Training on Da Vinci simulator in our institute (two simulators available in our training center ITQAN simulation center [11]. Training on Da Vinci simulator in our institute (two simulators available in our training center ITQAN simulation center [11]. Case observation for colonic and rectal resections done by the senior robotic proctor, each trainee – on average – had 5 case observation. Case observation for colonic and rectal resections done by the senior robotic proctor, each trainee – on average – had 5 case observation. Each one of the trainees were expected to fulfill the above pre-requisites before embarking on hand on training under direct supervision. On average 30 h of simulated training (in designed center belong to Hamad Medical Corporation called ITQAN [8] was achieved by each of the trainees completing competence score in each module of simulation, in parallel to bedside assistance. Once the trainees complete the above pre-requisites, they proceed to hands-on training under direct supervision of the trainer. The training commences as per modules described in EARCS and assessed using the Global Assessments Score form (GAS) [8]. The EARCS contains four modules, each containing several components. These include robotic docking, colonic dissection, TME, and resection and anastomosis. Each component is scored from 1 to 6 (or not applicable if the step is not performed) with the scores given corresponding to the competence levels, the higher the score, the higher the competence level for each component. Each supervised operation was scored in real time by the proctor. On an average the trainees performed a median of 18 supervised procedures the duration of that range between 30 and 40 weeks before they were assessed for competence and were allowed to perform independent procedures. However, the challenge remained in difficult low rectal cancer where they occasionally needed help from senior robotic surgeon. Statistical analysis Intervals were grouped into five 3-year periods (2010–2012, 2013–2015, 2016–2018, 2019–2021, 2022–2024). For the adoption trend (Fig. 1), surgical approach was summarized by intended approach; cases converted to open were included within MIS lines. For all outcomes analyses (tables and multivariable models), approach was classified by final approach (as-treated); in that conversions were counted as open and the conversion rate was reported separately. For the adoption trend (Fig. 1), surgical approach was summarized by intended approach; cases converted to open were included within MIS lines. For all outcomes analyses (tables and multivariable models), approach was classified by final approach (as-treated); in that conversions were counted as open and the conversion rate was reported separately. Categorical outcomes were compared across periods (Cochran–Armitage trend) and between intervals (χ²). Patient-level multivariable logistic regression modeled R0, ≥ 12 nodes, CD ≥ III, and reoperation for leak with predictors: period [1–5], approach (Open [ref], Laparoscopic, Robotic), age, sex, BMI, ASA, site, and procedure. LOS was analyzed with linear regression using the same covariates. Two-sided α = 0.05. p-values considered significant if < 0.05. Results are presented as odds ratios (ORs) with 95% CIs. Categorical outcomes were compared across periods (Cochran–Armitage trend) and between intervals (χ²). Patient-level multivariable logistic regression modeled R0, ≥ 12 nodes, CD ≥ III, and reoperation for leak with predictors: period [1–5], approach (Open [ref], Laparoscopic, Robotic), age, sex, BMI, ASA, site, and procedure. LOS was analyzed with linear regression using the same covariates. Two-sided α = 0.05. p-values considered significant if < 0.05. Results are presented as odds ratios (ORs) with 95% CIs. All analyses were performed in IBM SPSS Statistics version 29.0 (IBM Corp., Armonk, NY). All analyses were performed in IBM SPSS Statistics version 29.0 (IBM Corp., Armonk, NY). Surgical approaches by interval (2010–2024). The curve shows the cases as the procedure starts, MIS: started as MIS including conversions, open: Intended and started as open Ethical considerations The Institutional Review Board of Hamad Medical Corporation approved the study (MRC-01–25−1012). Data were collected in routine clinical practice and patient confidentiality was strictly maintained throughout the analysis. Results Patient and tumor characteristics A total of 1,142 patients underwent elective oncologic colorectal surgery over the 15-year period. The patients distributed into five consecutive time intervals: 2010–2012 (n = 162), 2013–2015 (n = 180), 2016–2018 (n = 204), 2019–2021 (n = 268), and 2022–2024 (n = 328). Baseline demographic and clinical characteristics were similar across the five periods. Median age ranged from 56 years in 2010–2012 to 51 years in 2022–2024. Median BMI showed a small increased trend from 25.0 kg/m² in 2010–2012 to 27.0 kg/m² in 2019–2024 but did not differ significantly across intervals (p = 0.33). American Society of Anesthesiologists (ASA) physical status was also stable, with 71.6–77.2% classified as ASA I–II and 22.8–28.4% as ASA III–IV. Tumor location was predominantly colonic in all periods (67.9% → 72.6%), with rectal cancers comprising the remainder. In the rectal cancer subgroup, the median distance from the anal verge remained essentially unchanged across cohorts (approximately 8.0–8.5 cm Overall, there were no statistically significant differences in the measured baseline variables between time intervals (Table 2). Table 2Patient and tumor characteristicsVariable2010–2012 (n = 162)2013–2015 (n = 180)2016–2018 (n = 204)2019–2021 (n = 268)2022–2024 (n = 328)P-valueAge, years, median (IQR)56 (30–83)54 (27–82)52 (26–84)53 (25–85)51 (24–86)0.41Female, n (%)53 (32.7)69 (38.3)80 (39.2)98 (36.6)115 (35.1)0.57BMI, kg/m², median (IQR)25 (18–41)26 (19–43)26 (17–42)27 (18–44)27 (19–45)0.33ASA I–II, n (%)116 (71.6)139 (77.2)153 (75.0)202 (75.4)244 (74.4)0.62ASA III–IV, n (%)46 (28.4)41 (22.8)51 (25.0)66 (24.6)84 (25.6)—Tumor location – Colon, n (%)110 (67.9)127 (70.6)150 (73.5)197 (73.5)238 (72.6)0.71Tumor location – Rectum, n (%)52 (32.1)53 (29.4)54 (26.5)71 (26.5)90 (27.4)—Distance from anal verge (cm)(rectal cancer only, median [IQR])8.4 (5–11)8.2 (5–10)8.0 (5–10)8.5 (5–10)8.3 (5–10)0.78 Patient and tumor characteristics Distance from anal verge (cm) (rectal cancer only, median [IQR]) Cohorts and adoption MIS use increased steadily from 51.2% (2010–2012) to 93.6% (2022–2024), while planned open cases decreased from 41.3% to 4.5%; conversions decreased from 7.4% to 1.8% (trend p < 0.001 for MIS; trend p = 0.004 for conversions). Robotic adoption expanded after 2020, reaching 31.1% of all cases in 2022–2024. Fig. 1 (intended approach; conversions grouped within MIS/laparoscopy) and Table 3 (as-treated counts with conversions listed separately) depict the temporal shift toward minimally invasive platforms. These trends reflect a unit-wide, phased integration of laparoscopy and robotics. Table 3Temporal adoption of surgical approaches across five intervalsPeriodCasesAll MIS (completed) N (%)Robotic† N (%)Open (Intended) N (%)Conversion* N (%)2010–201216283 (51.2%)0 (0%)67 (41.4%)12 (7.4%)2013–2015180126 (70%)0 (0%)45 (25.0%)9 (5.0%)2016–2018204167 (81.8%)4 (2.0%)27 (13.2%)10 (5.0%)2019–2021268238 (88.8%)32 (12.0%)21 (7.8%)9 (3.3%)2022–2024328307 (93.6%)102 (31.0%)15 (4.5%)6 (1.8%)p for trend< 0.001< 0.001< 0.0010.004p for trend from linear-by-linear association (2×k), treating period as ordinalMIS Minimally invasive surgery† Subset of MIS*Conversions from intended MIS to open; listed separately here and analyzed as open (“as-treated”) in outcomes and multivariable models Temporal adoption of surgical approaches across five intervals p for trend from linear-by-linear association (2×k), treating period as ordinal MIS Minimally invasive surgery † Subset of MIS *Conversions from intended MIS to open; listed separately here and analyzed as open (“as-treated”) in outcomes and multivariable models Segment removed Across the cohort (regardless of approach), procedures comprised right hemicolectomy 27.0%, extended right hemicolectomy 7.0%, segmental left hemicolectomy 9.9%, subtotal colectomy 2.1%, anterior resection 26.0%, low anterior resection/total mesorectal excision (TME) 24.0%, and abdominoperineal resection (APR) 4.0%. Oncologic quality and safety (unadjusted trends) Oncologic quality improved over time. R0 resections increased from 87.6% to 96.0% (trend p < 0.001) and adequate lymph node harvest (≥ 12 nodes) from 88.8% to 96.9% (trend p < 0.001) (Fig. 2). Oncologic quality over time: % R0 and % ≥12 lymph nodes by interval (both increasing, p < 0.001) Complications declined numerically—CD ≥ III complications 12.3%→8.8% and reoperation for leak 4.3%→2.1%—but trends were not statistically significant (p = 0.17 and p = 0.14, respectively) (Fig. 3). Safety outcomes over time: % CD ≥ III and % reoperation for leak (both decreasing; trend not significant) Length of stay Mean LOS decreased across periods for both approaches and remained consistently shorter with MIS (Fig. 4). By interval, LOS for MIS declined 8.0→5.5 days, and for open 11.0→7.5 days; overall, mean LOS was 6.4 days for MIS vs. 8.4 days for open. This pattern persisted in adjusted analyses. Length of stay by interval and approach: MIS consistently shorter than open Multivariable models (adjusted effects) In patient-level logistic regression adjusting for time (period index 1–5), approach (open, laparoscopic, robotic), age, sex, BMI, ASA, site, and procedure, we observed: R0 resection: time per 3-year step OR 1.45 (95% CI 1.21–1.74; p < 0.001); laparoscopic vs. open OR 0.66 (0.36–1.20; p = 0.18); robotic vs. open OR 0.62 (0.22–1.76; p = 0.37). Higher odds of R0 were associated with time/experience, not approach. R0 resection: time per 3-year step OR 1.45 (95% CI 1.21–1.74; p < 0.001); laparoscopic vs. open OR 0.66 (0.36–1.20; p = 0.18); robotic vs. open OR 0.62 (0.22–1.76; p = 0.37). Higher odds of R0 were associated with time/experience, not approach. ≥ 12 lymph nodes: time OR 1.43 (1.17–1.75; p < 0.001); laparoscopic vs. open OR 0.72 (0.37–1.38; p = 0.32); robotic vs. open OR 1.96 (0.40–9.66; p = 0.41). Node adequacy improved over time; approach was not significant. ≥ 12 lymph nodes: time OR 1.43 (1.17–1.75; p < 0.001); laparoscopic vs. open OR 0.72 (0.37–1.38; p = 0.32); robotic vs. open OR 1.96 (0.40–9.66; p = 0.41). Node adequacy improved over time; approach was not significant. CD ≥ III complications: time OR 0.92 (0.79–1.08; p = 0.31); laparoscopic vs. open OR 1.15 (0.68–1.94; p = 0.61); robotic vs. open OR 0.75 (0.30–1.84; p = 0.53). No adjusted association with approach; non-significant time trend. CD ≥ III complications: time OR 0.92 (0.79–1.08; p = 0.31); laparoscopic vs. open OR 1.15 (0.68–1.94; p = 0.61); robotic vs. open OR 0.75 (0.30–1.84; p = 0.53). No adjusted association with approach; non-significant time trend. Reoperation for leak: time OR 0.84 (0.64–1.10; p = 0.20); laparoscopic vs. open OR 1.82 (0.65–5.08; p = 0.25); robotic vs. open OR 0.41 (0.04–4.04; p = 0.45). No adjusted association detected. Reoperation for leak: time OR 0.84 (0.64–1.10; p = 0.20); laparoscopic vs. open OR 1.82 (0.65–5.08; p = 0.25); robotic vs. open OR 0.41 (0.04–4.04; p = 0.45). No adjusted association detected. Length of stay (linear model): laparoscopic vs. open − 2.34 days (95% CI − 2.79 to − 1.88; p < 0.001); robotic vs. open − 2.39 days (− 3.08 to − 1.69; p < 0.001); time − 0.60 days per step (− 0.73 to − 0.46; p < 0.001). MIS independently reduced LOS, with additional improvement over time. Length of stay (linear model): laparoscopic vs. open − 2.34 days (95% CI − 2.79 to − 1.88; p < 0.001); robotic vs. open − 2.39 days (− 3.08 to − 1.69; p < 0.001); time − 0.60 days per step (− 0.73 to − 0.46; p < 0.001). MIS independently reduced LOS, with additional improvement over time. Adjusted effects are visualized in Figs. 5, 6, 7 and 8 (forest plots). Together, these models indicate that gains in oncologic quality were primarily time-related (unit maturation), whereas MIS conferred a robust LOS advantage independent of period effects. Approach was not associated with major complications or reoperation for leak after adjustment. Adjusted odds ratios for R0 (logistic regression: time, approach, covariates) Adjusted odds ratios for ≥ 12 lymph nodes Adjusted odds ratios for CD ≥ III complications Adjusted odds ratios for reoperation for anastomotic leak Table 4 summarizes LOS, R0, LN adequacy, CD ≥ III, and leak across intervals and overall (as-treated; conversions counted as open), aligning with Figs. 2, 3 and 4. These period-level trends are directionally consistent with the adjusted effects reported above. Table 4Outcomes by interval; values are n (%) unless noted. LOS = mean days by approach. As-treated classification with conversions counted as open (see Table 3)Outcome2010–2012N: 1622013–2015N:1802016–2018N: 2042019–2021N: 2682022–2024N: 328OverallN: 1142p value for the trend*LOS days MIS/Open,8/117/96.4/86/7.85.5/7.56.4/8.4< 0.001R0 Resection142 (87.6%)160 (88.8%)188 (92.2%)252 (94.0%)315 (96.0%)1057 (92.6%)< 0.001≥ 12 LN Yield144 (88.8%)164 (91.1%)194 (95.1%)257 (95.9%)318 (96.9%)1077 (94.3%)< 0.001CD ≥ III20 (12.3%)20 (11.1%)20 (9.8%)24 (8.9%)29 (8.8%)113 (9.9%)0.17Leak Requiring Surgery7 (4.3%)6 (3.3%)5 (2.5%)6 (2.2%)7 (2.1%)31 (2.7%)0.14Abbreviations: MIS Minimally invasive surgery, LOS Length of stay, LN Lymph nodes, CD ≥ III Clavien–Dindo grade ≥ III*p for trend from linear-by-linear association (categorical outcomes) and linear trend across means (LOS) Outcomes by interval; values are n (%) unless noted. LOS = mean days by approach. As-treated classification with conversions counted as open (see Table 3) Abbreviations: MIS Minimally invasive surgery, LOS Length of stay, LN Lymph nodes, CD ≥ III Clavien–Dindo grade ≥ III *p for trend from linear-by-linear association (categorical outcomes) and linear trend across means (LOS) Discussion This paper evaluated our 15-year experience with centralization of specialized colorectal cancer service with progressive adoption of MIS at a tertiary care hospital. The phased introduction of laparoscopic and subsequently robotic approaches was undertaken alongside the structured development of the unit, including dedicated multidisciplinary pathways, standardized operative training, and continuous outcome monitoring. Beyond reaffirming the value of specialized colorectal pathways, our contribution is a pragmatic framework for stepwise MIS adoption. By sequencing simulation and proctored cases, setting explicit credentialing thresholds, codifying escalation/conversion policies, and auditing KPIs in a live registry, we observed increased MIS use alongside improvements in oncologic and perioperative outcomes. We provide phase definitions, credentialing criteria, and KPIs so that developing units can adapt the model to their resources and case-mix. This dedicated process of unit development enabled a safe and significant transition from open to minimally invasive techniques. Our findings showed that the unit transformation was associated with progressive improvements in oncologic quality, enhanced operative efficiency, and a steady decrease in postoperative complications, confirming the critical role of specialization and institutional growth in achieving high-quality outcomes. Over the past few decades, colorectal surgery has undergone a significant shift from open procedures toward less invasive alternatives, including laparoscopic and robotic surgery [12]. This evolution has been driven by the well-established advantages of laparoscopic surgery, such as reduced postoperative pain, decreased opioid requirements, shorter hospital stays, and faster recovery of bowel function. Robotic surgery, emerging more recently, offers enhanced three-dimensional visualization, improved ergonomics, and the ability to overcome some of the technical limitations of traditional laparoscopy [13–15]. In our colorectal unit, we observed a significant increase in the adoption of MIS over the open surgery throughout the study period, reaching 93% in the most recent 3-year interval. This trend aligns global patterns and is consistent with the findings from the recent study by Azevedo et al., who reported a 90% adoption rate of MIS among 661 patients undergoing colorectal cancer resection at the Champalimaud Foundation in Portugal between 2012 and 2023 [13]. In our study, there was a significant reduction in LOS days. The mean LOS was 6.4 days for MIS compared with 8.4 days for open surgery, decreasing to 5.5 days in the most recent period. Our findings align with published literature, reflecting the impact of unit specialization and structured MIS adoption. The COLOR II trial reported median stays of 8 days for laparoscopic versus 9 days for open surgery, the ACOSOG Z6051 trial found means of 7.3 versus 7.0 days, and the ROLARR trial reported 8 days for both approaches. Specialized centers often achieve even shorter stays. Such as, a large Italian colorectal unit reported median LOS 6 days for laparoscopic resections (vs. 9 days open) [16]. A recent U.S. center found mean LOS 4.35 days after minimally-invasive rectal surgery (vs. 8.48 days for open) [17]. Moreover, these findings align closely with the Azevedo et al. study, which reported a median length of stay of 6.7 days. Krieg et al., documented a mean hospital stay of 11 days among 4,525 colorectal cancer patients undergoing MIS across 36 hospitals in Germany [18]. The maturation and specialization of our colorectal service were central to the outcomes reported. Beginning with the formal establishment of a centralized colorectal unit in 2010, the team introduced an institutional MDT in 2011 (restructured to a dedicated colorectal MDT in 2018) and phased a structured MIS and robotic adoption pathway (first robotic case was 2017). These programmatic milestones, combined with standardized operative modules, stepwise proctoring, and continuous outcome audit, coincided with a progressive shift from open to minimally invasive surgery (51.2% → 93.6%) and a marked reduction in conversions (7.4% → 1.8%). Moreover, oncologic quality improved in parallel, as R0 increase from 87.6% to 96.0%; and ≥ 12 nodes from 88.8% to 96.9%. A multivariable models showed that calendar time/unit experience (per 3-year step) was the dominant predictor of R0 and node adequacy, supporting a systems-level rather than technique-specific explanation for these findings. At the same time, MIS adoption provides consistent efficiency benefits, up to 2-day reduction in length of stay, without compromising safety. Together, these findings highlight that safe MIS implementation depends less on isolated technology and more on institutional design, centralization, sustained subspecialization, and structured training were key enablers of high-quality, efficient colorectal cancer care in our unit. We observed a rising rate of R0 resections over the study period, with an overall R0 rate of 92%, indicating a high level of oncologic adequacy across our cohort. While this finding reflects the successful transition from open to minimally invasive techniques without loss of surgical quality, our multivariable analyses indicate that these findings were more strongly associated with the unit maturation and specialization than with surgical approach, after adjustment there was no independent difference in R0 rates between open and MIS procedures. These results are consistent with those reported by Azevedo et al., who observed a 95% R0 resection rate in their cohort, and are supported by major randomized controlled trials in both colon and rectal cancer, such as the COLOR II and ACOSOG trials [13, 19–23]. A major concern during the transition to MIS is the potential for increased perioperative complications during the learning curve and training phases. Interestingly, our study demonstrated a notable decline in complication rate, presented as CD ≥ 3, throughout the study period with an overall rate of 9.9%. This is lower than previously published articles, including the ACOSOG trial that reported severe complications (CD ≥ 3) in up to 22% of patients undergoing laparoscopic resection [22], and also lower than ALaCaRT trial [23]. Our results are comparable to those of Azevedo et al., who reported a 11% rate of CD ≥ 3 complications [13]. Regarding the anastomotic leak, we observed a progressive decline in leakage rates over time, reaching 2.1% in the final study period. However, the trend didn’t reach statistical significance (P = 0.14). The overall rate is 2.7% which is appropriate in comparison to previously published data, including 4.2% in Azevedo et al., 8.5% in the CLASICC trial, 11% in the ROLARR trial, and 12% in the COLOR II trial [13, 19–21]. The incidence of anastomotic leak is multifactorial and influenced by perioperative chemotherapy, tumor characteristics, the type and location of the anastomosis, use of diverting stomas, surgeon experience, patient comorbidities, and quality of postoperative care. Strength and limitations The strengths of our study are its Large, contemporary cohort (N = 1,142) spanning 15 years, enabling robust temporal analyses, additionally the prospectively maintained database with predefined outcomes improved data completeness. The clear implementation timeline (centralized unit, MDT, robotics) allowed phase-wise evaluation of adoption. Lastly multivariable adjustment for case-mix (age, sex, BMI, ASA, site, procedure). The limitations included the retrospective, single-center design that may limit generalizability, the period (“time/experience”) may also capture secular improvements (Anesthesia, peri-operative oncology). Moreover, potential selection bias and unmeasured confounding (e.g., tumor stage, neoadjuvant therapy, anastomotic level/diversion, comorbidities). We studied only the short-term outcomes, and for best understanding long-term oncologic and functional outcomes need to be assessed. Future directions Incorporate tumor stage and neoadjuvant variables; perform rectal-only stratifications; consider mixed-effects models with surgeon clustering; add sensitivity analyses by intended approach; and report long-term oncologic and functional outcomes as the program matures. Conclusion Over 15 years, centralization and subspecialization within our colorectal unit enabled the safe and effective adoption of laparoscopic and robotic surgery, yielding a marked shift away from open procedures. This transition occurred without compromising safety or oncologic outcomes and was associated with shorter hospital stays. In adjusted analyses, improvements were independently associated with the unit’s development. Key enablers included service centralization, subspecialist surgeons, a structured unit-progression framework, and a strengthened multidisciplinary team (MDT) process, which together supported the safe, progressive uptake of MIS. Acknowledgements None. Authors’ contributions A.T. and H.A.A. wrote the main manuscript text and prepared figures and tables. S.A., A.A., M.D., I.A., M.Kh., Am.A., E.L., Sa.A., M.Y., N.A.N. and M.Abu collected and verified patient, operative and pathology data. A.T. performed the statistical analyses and contributed to drafting the Methods and Results. All authors reviewed, edited and approved the final manuscript and agree to be accountable for all aspects of the work. Funding None. Data availability the data will be available on reasonable request. Declarations Ethical approval and consent to participate The Institutional Review Board of Hamad Medical Corporation approved the study (MRC-01-25-1012). Data were collected in routine clinical practice and patient confidentiality was strictly maintained throughout the analysis. Due to the retrospective nature of the study, The Institutional Review Board of Hamad Medical Corporation approved the study (MRC-01-25-1012) waived the need to obtain informed consent. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement the data will be available on reasonable request.